Your browser doesn't support javascript.
loading
Nanomolar anti-SARS-CoV-2 Omicron activity of the host-directed TMPRSS2 inhibitor N-0385 and synergistic action with direct-acting antivirals.
Pérez-Vargas, Jimena; Lemieux, Gabriel; Thompson, Connor A H; Désilets, Antoine; Ennis, Siobhan; Gao, Guang; Gordon, Danielle G; Schulz, Annika Lea; Niikura, Masahiro; Nabi, Ivan Robert; Krajden, Mel; Boudreault, Pierre-Luc; Leduc, Richard; Jean, François.
Afiliação
  • Pérez-Vargas J; Department of Microbiology and Immunology, Life Sciences Institute, University of British Columbia, Vancouver, BC, Canada.
  • Lemieux G; Department of Pharmacology-Physiology, Faculty of Medicine and Health Sciences, Institut de Pharmacologie de Sherbrooke, Université de Sherbrooke, Sherbrooke, Québec, Canada.
  • Thompson CAH; Department of Microbiology and Immunology, Life Sciences Institute, University of British Columbia, Vancouver, BC, Canada.
  • Désilets A; Department of Pharmacology-Physiology, Faculty of Medicine and Health Sciences, Institut de Pharmacologie de Sherbrooke, Université de Sherbrooke, Sherbrooke, Québec, Canada.
  • Ennis S; Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada.
  • Gao G; Department of Microbiology and Immunology, Life Sciences Institute, University of British Columbia, Vancouver, BC, Canada; Department of Cellular and Physiological Sciences, Life Sciences Institute, University of British Columbia, Vancouver, BC, Canada.
  • Gordon DG; Department of Microbiology and Immunology, Life Sciences Institute, University of British Columbia, Vancouver, BC, Canada.
  • Schulz AL; Department of Microbiology and Immunology, Life Sciences Institute, University of British Columbia, Vancouver, BC, Canada.
  • Niikura M; Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada.
  • Nabi IR; Department of Cellular and Physiological Sciences, Life Sciences Institute, University of British Columbia, Vancouver, BC, Canada.
  • Krajden M; British Columbia Centre for Disease Control Public Health Laboratory, Vancouver, BC, V5Z 4R4, Canada; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, V6T 1Z3, Canada.
  • Boudreault PL; Department of Pharmacology-Physiology, Faculty of Medicine and Health Sciences, Institut de Pharmacologie de Sherbrooke, Université de Sherbrooke, Sherbrooke, Québec, Canada.
  • Leduc R; Department of Pharmacology-Physiology, Faculty of Medicine and Health Sciences, Institut de Pharmacologie de Sherbrooke, Université de Sherbrooke, Sherbrooke, Québec, Canada. Electronic address: richard.leduc@usherbrooke.ca.
  • Jean F; Department of Microbiology and Immunology, Life Sciences Institute, University of British Columbia, Vancouver, BC, Canada. Electronic address: fjean@mail.ubc.ca.
Antiviral Res ; 225: 105869, 2024 May.
Article em En | MEDLINE | ID: mdl-38548023
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Sulfonamidas / Benzotiazóis / COVID-19 Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Sulfonamidas / Benzotiazóis / COVID-19 Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article